NO20066079L - Behandlingsmetode for cancer - Google Patents

Behandlingsmetode for cancer

Info

Publication number
NO20066079L
NO20066079L NO20066079A NO20066079A NO20066079L NO 20066079 L NO20066079 L NO 20066079L NO 20066079 A NO20066079 A NO 20066079A NO 20066079 A NO20066079 A NO 20066079A NO 20066079 L NO20066079 L NO 20066079L
Authority
NO
Norway
Prior art keywords
administering
cancer
treating cancer
treatment
relates
Prior art date
Application number
NO20066079A
Other languages
English (en)
Inventor
Mark S Berger
Tona Morgan Gilmer
Arundathy Nirmalini Pandite
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of NO20066079L publication Critical patent/NO20066079L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Foreliggende oppfinnelse angår en metode for behandling av kreft hos et pattedyr, ved administrering av 4-kinazolinaminer og minst én ytterligere antineoplastisk forbindelse. Spesielt angår metoden metoder for behandling av kreft ved administrering av N-{3-klor-4-[(3-fluorbenzyl)oksy]fenyl}-6-[5-({[2-(metansulfonyl)etyl]amino}metyl)-2-furyl]-4-kinazolinamin, og salter og solvater derav, i kombinasjon med minst én ytterligere anti-neoplastisk forbindelse.
NO20066079A 2004-06-04 2006-12-29 Behandlingsmetode for cancer NO20066079L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57733704P 2004-06-04 2004-06-04
PCT/US2005/019568 WO2005120512A2 (en) 2004-06-04 2005-06-03 Cancer treatment method

Publications (1)

Publication Number Publication Date
NO20066079L true NO20066079L (no) 2007-01-12

Family

ID=35503649

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20066079A NO20066079L (no) 2004-06-04 2006-12-29 Behandlingsmetode for cancer

Country Status (14)

Country Link
US (1) US20090317383A1 (no)
EP (1) EP1765344A4 (no)
JP (1) JP2008501708A (no)
KR (1) KR20070034536A (no)
CN (2) CN101564535A (no)
AU (2) AU2005251769B2 (no)
BR (1) BRPI0511765A (no)
CA (1) CA2569139A1 (no)
IL (1) IL179323A0 (no)
MA (1) MA28901B1 (no)
MX (1) MXPA06013952A (no)
NO (1) NO20066079L (no)
RU (2) RU2361589C2 (no)
WO (1) WO2005120512A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066267A2 (en) * 2004-12-17 2006-06-22 Smithkline Beecham (Cork) Limited Cancer treatment method
WO2007143483A2 (en) * 2006-06-01 2007-12-13 Smithkline Beecham Corporation Combination of pazopanib and lapatinib for treating cancer
JP2010501572A (ja) * 2006-08-22 2010-01-21 コンサート ファーマシューティカルズ インコーポレイテッド ４−アミノキナゾリン誘導体およびその使用方法
EA200970353A1 (ru) 2006-10-06 2009-10-30 Такеда Фармасьютикал Компани Лимитед Комбинированное лекарственное средство
WO2008067144A2 (en) * 2006-11-28 2008-06-05 Smithkline Beecham (Cork) Limited Cancer treatment method
AU2008205457A1 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual TKI therapy
EP2255830A1 (en) 2008-03-03 2010-12-01 Takeda Pharmaceutical Company Limited Concomitant drug
WO2009137714A2 (en) 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
EP2393488B1 (en) 2009-02-06 2019-06-19 University Of Southern California Therapeutic compositions comprising monoterpenes
US8568968B2 (en) 2009-04-13 2013-10-29 University Of Southern California EGFR polymorphisms predict gender-related treatment
US20140302050A1 (en) * 2011-11-09 2014-10-09 Albert Einstein College Of Medicine Of Yeshiva University Targeting an amphiregulin-derived cell surface neo-epitope

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
CN1261275A (zh) * 1997-05-27 2000-07-26 巴克·诺顿药物有限公司 给予病人口服紫杉烷类药物的方法和组合物
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
CA2401191C (en) * 2000-02-28 2006-05-02 Aventis Pharma S.A. A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
AU2001273071B2 (en) * 2000-06-30 2005-09-08 Glaxo Group Limited Quinazoline ditosylate salt compounds
DE60203260T2 (de) * 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
EP1653986A4 (en) * 2003-08-01 2007-03-14 Smithkline Beecham Corp TREATMENT OF P95 ERBB2 EXPRESSIVE CARCINOMA
US8211030B2 (en) * 2009-03-26 2012-07-03 The General Electric Company NIBP target inflation pressure automation using derived SPO2 signals

Also Published As

Publication number Publication date
RU2361589C2 (ru) 2009-07-20
WO2005120512A2 (en) 2005-12-22
MA28901B1 (fr) 2007-10-01
CA2569139A1 (en) 2005-12-22
CN1984656B (zh) 2010-05-26
CN101564535A (zh) 2009-10-28
EP1765344A4 (en) 2009-12-02
US20090317383A1 (en) 2009-12-24
IL179323A0 (en) 2007-05-15
CN1984656A (zh) 2007-06-20
AU2005251769A1 (en) 2005-12-22
EP1765344A2 (en) 2007-03-28
AU2008229859A1 (en) 2008-10-30
MXPA06013952A (es) 2007-02-08
AU2005251769B2 (en) 2008-10-02
RU2006142418A (ru) 2008-07-20
KR20070034536A (ko) 2007-03-28
RU2008150250A (ru) 2010-06-27
JP2008501708A (ja) 2008-01-24
BRPI0511765A (pt) 2008-01-08
WO2005120512A3 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
NO20072631L (no) Kreftbehandlingsmetode
NO20066079L (no) Behandlingsmetode for cancer
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
NO20072055L (no) Fremgangsmater og sammensetninger for behandling av flaviviruser, pestiviruser og hepacivirus
WO2007143483A3 (en) Combination of pazopanib and lapatinib for treating cancer
NO20070453L (no) Kondenserte heterocykliske kinase inhibitorer
NO20081963L (no) Fremgangsmate for behandling
NO20074366L (no) Fremgangsmate for a behandle gefitmibresistent kreft
IL248049A0 (en) Sns-595 and methods of using the same
NO20082683L (no) Neuroendokrin tumorbehandling
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
EA200800932A1 (ru) Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
NO20070593L (no) Amyloid-avbildning som erstatningsmarkor ved antiamyloid terapi.
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
CY1110620T1 (el) Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας
WO2008067144A3 (en) Cancer treatment method
CY1109087T1 (el) Ενωση ιμιδαζο[4,5-c]πυριδινης και μεθοδος αντι-ιικης θεραπειας
DK1715890T3 (da) CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati
EA201000630A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
NO20066077L (no) Behandlingsmetode for cancer
BR0311223A (pt) Método para o uso de derivados de piranindol para tratar infecção pelo vìrus da hepatite c
PT1642576E (pt) Utilização de derivados de pirrole para combate da ansiedade
WO2006026313A3 (en) Cancer treatment method

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application